# Bioequivalence Study of CJ-30061 in Healthy Male Volunteers

> **NCT03657472** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 42 (actual)

## Conditions studied

- Hypertension
- Hyperlipidemia

## Interventions

- **DRUG:** CJ-30061
- **DRUG:** Exforge® 5/160mg & Lipitor® 20mg

## Key facts

- **NCT ID:** NCT03657472
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-19
- **Primary completion:** 2016-10-29
- **Final completion:** 2016-11-09
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657472, "Bioequivalence Study of CJ-30061 in Healthy Male Volunteers". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT03657472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*